Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality

The use of senolytic agents to remove senescent cells from atherosclerotic lesions is controversial. A common limitation of previous studies is the failure to rigorously define the effects of senolytic agent ABT-263 (Navitoclax) on smooth muscle cells (SMC) despite studies claiming that these cells...

Full description

Bibliographic Details

Published in:	JCI Insight
Main Authors:	Santosh Karnewar, Vaishnavi Karnewar, Laura S. Shankman, Gary K. Owens
Format:	Article
Language:	English
Published:	American Society for Clinical investigation 2024-01-01
Subjects:	Vascular biology
Online Access:	https://doi.org/10.1172/jci.insight.173863